Tests for POC and Homeland Defense

Exclusive rights to market an innovative line of rapid-result blood and urine tests have been granted to QT 5, Inc. (Westlake Village, CA, USA; www.qt5inc.com) by an undisclosed source. The diagnostic platform was specifically designed for point-of-care (POC) and ambulatory use as well as for the emerging homeland defense market.

The patented test platform incorporates a combination of a solid phase membrane and immunologic-based reagents in a single-use disposable test device. The platform has the capacity for providing rapid POC testing for a wide variety of medical conditions. The diagnostic platform is highly flexible and capable of testing for important infectious diseases, drugs, and drug metabolites. Depending upon the application, this platform technology may provide either quantitative or qualitative test results in minutes with a high degree of accuracy.

QT 5 will include in its initial product offering a low-cost, small-footprint desktop analyzer designed for use with the rapid test cartridges. A handheld mobile version of the multiple assay analyzer will be compatible with a wide variety of new tests being developed for use by paramedics, assisted-living facilities, and military groups. QT 5 has developed another line of qualitative fast tests for rubella, herpes virus, rotavirus, strep group A, and infectious mononucleosis that have been cleared by the U.S. Food and Drug Administration (FDA).




Related Links:
QT 5